Eye care products gave a boost to Allergan, as third-quarter sales in that division grew by 4.8 percent to $535.1 million, an 8 percent increase in constant currencies. The growth for the overall company was 4.2 percent to $1.13 billion, a 7 percent increase on a currency-neutral basis. Net earnings were 8.0 percent higher at $179.2 million. For the first nine months of 2009, eye care sales dropped by 0.5 percent to $1.53 billion, though this was an increase of 4.4 percent in constant currencies. Overall, Allergan's sales dropped by 1.7 percent to $3.24 billion, and net income fell by 4.0 percent to $401 million.